Problem

Kalinda addresses two closely related bottlenecks in plaintiff-side law: converting incoming personal-injury leads into signed matters and rapidly vetting large volumes of mass-tort or class-action claims. For personal-injury firms, calls, web forms, referrals, missed calls, after-hours inquiries, and overflow leads can go unanswered or receive a slow callback, causing firms to lose cases even when the leads are already arriving. For mass-tort firms, proof of product use, injury, treatment, and liability is buried across thousands of pages of medical, financial, employment, and other records. The work is slow, expensive, and error-prone: what can take months manually can delay deadlines, leave firms buried in records, and weaken settlement leverage when weak claims are filed.

The economic opportunity is therefore a combination of labor leverage, faster case selection, and greater claim throughput. Kalinda's stated killer use cases are turning an injury call into a signed retainer without a handoff, and helping mass-tort firms determine which claimants are eligible so they can file valid cases faster and in greater volume. The company positions this as equivalent capacity to hundreds or thousands of paralegals and legal nurses, while public materials do not disclose pricing, margins, or revenue.

Product / Service

Kalinda's current website presents an AI intake specialist for personal-injury firms. It answers inbound calls, calls back web forms, referrals, missed leads, and after-hours inquiries, conducts the firm's prescribed intake, gathers facts, qualifies the matter, and sends the retainer for signature. The workflow is designed to run from the first conversation to a signed case across voice and text, with the claimed benefit of capturing more usable case data while reducing human escalation and broken handoffs.

Kalinda's broader public product materials describe AI agents and a document-analysis platform for personal-injury, mass-tort, and class-action work. The system reads large medical and legal-record collections, extracts structured facts such as proof of use and injury, correlates them against lawsuit criteria, and produces reports, dashboards, and medical chronologies. Kalinda says it generated a chronology from 3,000 pages in 20 minutes and can produce court-ready chronologies in about 15 minutes, allowing attorneys to spend less time on repetitive review and more time on clients, strategy, and advocacy. Uploaded records are processed through a law-firm platform that generates reports and maintains a case-viewing dashboard, with the privacy policy describing HIPAA-related handling of protected health information.

Market

Kalinda competes in vertical legal technology, specifically AI-powered legal intake, medical-record review, claimant qualification, and mass-tort operations for plaintiff-side firms. Its competitive set is fragmented rather than limited to one direct rival. FinLegal is an adjacent mass-tort platform covering intake, qualification, evidence gathering, fraud detection, and document generation; DigitalOwl focuses on AI medical-record review and evidence-based decision workflows for legal and insurance users; and ProPlaintiff.ai targets personal-injury firms with AI-assisted case-file analysis, medical chronologies, demand letters, and document automation. Wisedocs, UiPath, and Datavant also appear in third-party market listings as possible broader alternatives for document and data automation.

The evidence indicates that Kalinda is an early but operating commercial company, not merely a concept. Y Combinator lists it as an active Summer 2025 company, and its launch materials reported 600,000 pages of records processed and live deployments with two of the largest U.S. plaintiff law firms. The current personal-injury site reports a case study with 545 intake calls handled, 98.3% of live calls producing usable case data, and 95.7% handled without human escalation; its medical-chronology page also cites use by attorneys at top firms. A third-party profile reports a $500,000 seed round in September 2025, but the available evidence does not establish revenue, ARR, or pricing, so its revenue status cannot be confirmed from the public record reviewed.